Alamar Biosciences Inc (ALMR) Stock AnalysisALMRAlamar Biosciences Inc

Alamar Biosciences, Inc. is a commercial-stage proteomics company engaged in protein detection and analysis. The Company's proprietary NULISA (Nucleic Acid Linked Immuno-Sandwich Assay) technology addresses the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, dynamic range and automation. Its integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundances and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics. Its instrument, the ARGO HT System, is designed to automate high-sensitivity and high-plex proteomics analysis and is available for research use only applications. It operates in the Healthcare sector.

Alamar Biosciences, Inc. is currently not a strong buy due to its recent price drop of 26.46% over the past five days and a low RSI of 26.806, indicating it is oversold. However, the company reported a significant revenue growth of 82% year-over-year in Q2 2026, reaching $29.4 million, and has a gross margin of 60.21%, which shows potential for profitability. The main risk is the widening net loss of $13.19 million in Q2 2026, which could deter investors.